Fate Therapeutics, Inc.FATENASDAQ
Loading
EV to Sales: Discounted ValuationCompressed
Percentile Rank50
3Y CAGR+27.9%
5Y CAGR-37.6%
Year-over-Year Change
Enterprise value to sales ratio
3Y CAGR
+27.9%/yr
vs -44.8%/yr prior
5Y CAGR
-37.6%/yr
Recent acceleration
Acceleration
+72.7pp
Accelerating
Percentile
P50
Within normal range
vs 5Y Ago
0.1x
Contraction
Streak
2 yr
Consecutive growthCompressed
| Period | Value | YoY Change |
|---|---|---|
| 2025 | 22.26 | +28.1% |
| 2024 | 17.37 | +156.8% |
| 2023 | 6.76 | -36.5% |
| 2022 | 10.64 | -89.2% |
| 2021 | 98.93 | -58.1% |
| 2020 | 236.09 | +99.9% |
| 2019 | 118.13 | +2.7% |
| 2018 | 115.05 | +159.0% |
| 2017 | 44.41 | +10872.3% |
| 2016 | 0.40 | - |